Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 1R01AR083552-01A1 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Institutes of Health (NIH) | NIH |
| National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | NIH |
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to perform a "muscle phenotyping" magnetic resonance imaging (MRI) assessment in patients receiving clinical care at the Children's Hospital of Philadelphia (CHOP) for mitochondrial disease that is either suspected (based on clinical presentation) or has a definite genetic diagnosis. The MRI assessment quantifies skeletal muscle oxidative phosphorylation (OXPHOS) capacity.
Investigators hope that this study will contribute to our current knowledge of mitochondrial diseases and this study will help create a new diagnostic tool for use in both clinical care and in clinical trials.
This research study visit will occur on the same day as the participants clinically scheduled MRI. The clinically indicated and study-specific scanning time will not exceed 120 minutes.
During the study visits:
If eligible participants return to CHOP for future clinical imaging, we will also request a study-specific MRI assessment.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Mitochondrial Disease | Individuals with suspected (based on clinical presentation) or definite genetic mitochondrial disease |
| |
| Healthy Controls/Volunteers | Individuals with no history of suspected (based on clinical presentation) or definite genetic mitochondrial disease |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Creatine Chemical Exchange Saturation Transfer (CrCEST) Imaging Sequence | Diagnostic Test | CrCEST be used to assess creatine distribution and concentrations in muscle (lower extremity), both at rest and after recovery from a brief foot-pedal depression exercise |
| Measure | Description | Time Frame |
|---|---|---|
| Post-exercise CrCEST recovery time (seconds) | The time it takes after the exercise occurs to recover CrCEST | During the MRI |
| Measure | Description | Time Frame |
|---|---|---|
| Resting CrCEST | Amount of CrCEST prior to exercise | During the MRI |
| Muscle Lipid Content | Includes both Intramyocellular lipid (IMCL) and extramyocellular lipids (EMCL) content, both expressed in arbitrary units relative to water signal and relative to creatine |
Not provided
Inclusion Criteria (Mitochondrial Disease Patients):
Inclusion Criteria (Healthy Controls):
Inclusion Criteria (Evaluable Healthy Controls and Cases for Data Analysis):
Exclusion Criteria (Mitochondrial Disease Patients and Healthy Controls):
Exclusion Criteria (Healthy Controls)
Not provided
Not provided
The study population consists of suspected or definite mitochondrial disease patients who are receiving clinical care through the Mitochondrial Medicine Frontier Program
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Zarazuela Zolkipli Cunningham, MBChB MRCP | Children's Hospital of Phiadelphia | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Children's Hospital of Philadelphia | Philadelphia | Pennsylvania | 19104 | United States |
Not provided
| ID | Term |
|---|---|
| D028361 | Mitochondrial Diseases |
| ID | Term |
|---|---|
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| During the MRI |
| Fat-fraction | n-point Dixon, expressed as a percentage of the total area | During the MRI |